In October’s Featured Publication, Dr. Sandro Santagata treated a patient with BRAF V600E mutated pleomorphic xanthroastrocytoma (PXA), a rare brain tumor in children and young adults. His team used Vemurafenib monotherapy  for the first time in the treatment of V600E-mutated glioma, and saw an encouraging response by the tumor to this approach, leading to the development of a clinical trial for further investigation of BRAF  and MEK inhibitors in combination.